CHRN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 14.02
- P/S (TTM)
- 21.73
- EV/EBITDA
- 475.46
Profitability & growth
- ROE (TTM)
- -38.5%
- Operating margin
- -60.0%
- Revenue growth YoY
- 148.1%
- Dividend yield
- —
- Beta
- 0.98
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About ChronoScale Corporation
Company profileChronoScale Corporation (Ticker: CHRN) is a cutting-edge biotechnology company dedicated to transforming healthcare by developing and commercializing innovative therapeutics that address unmet medical needs. The firm boasts a robust pipeline supported by strategic collaborations and is committed to leveraging advanced technologies to enhance patient care outcomes. Through its unwavering focus on scientific excellence and a dynamic approach to the evolving healthcare landscape, CHRN is strategically positioned to emerge as a prominent leader in the biotechnology sector, poised to capitalize on…
Classification
- Sector
- Technology
- Industry
- Information Technology Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3811 TURTLE CREEK BLVD., DALLAS, TX
- Fiscal year end
- May
- Latest quarter
- Aug 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
